Skip to main content

Press Releases

October 19, 2023
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to explore partnership opportunities for continued development of select programs Anticipated cost savings,
Displaying 1 - 10 of 20